Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with raised revenue guidance, geographic expansion, and strong pipeline development. The Q&A section reveals optimism about Joenja's growth in the U.S. and international markets, despite some uncertainties in patient conversion rates. Financial discipline and a focus on value-accretive transactions further enhance the positive sentiment. The optimistic guidance and strategic focus on expanding Joenja's market presence are likely to drive a positive stock price movement over the next two weeks.
Key Financial Performance
Total revenues (Q4 2025) $106.5 million, a 15% growth year-over-year, driven by continued momentum across the portfolio, including 9% growth for RUCONEST and 53% growth for Joenja.
Total revenues (Full Year 2025) $376.1 million, a 27% increase year-over-year, driven by robust double-digit growth from both RUCONEST and Joenja.
Operating profit (2025) $26 million, compared to a loss in 2024, attributed to disciplined cost management.
Operating cash flow (2025) $55 million, reflecting improved profitability and cash generation of the business.
RUCONEST revenue growth (2025) 26% year-over-year, with 9% growth in Q4, attributed to its efficacy, reliability, and rapid onset of action.
Joenja revenue growth (2025) 29% year-over-year, with 53% growth in Q4, driven by new patients in the U.S. and increased demand in international markets.
Cash and marketable securities (Year-end 2025) $181 million, an increase of $11.7 million from the previous year, despite $68 million used for the Abliva acquisition, highlighting strong operational cash generation.
Adjusted operating profit (2025) $36.4 million, compared to a loss of $8.6 million in 2024, excluding nonrecurring Abliva acquisition-related costs and other offsetting items.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RUCONEST: Achieved 26% year-on-year growth in 2025 and 9% growth in Q4. Positioned as a reliable on-demand treatment for severe HAE patients, especially those with high-frequency attacks. Added over 60 new enrollments in the U.S. in Q4.
Joenja: Achieved 29% year-on-year growth in 2025 and 53% growth in Q4. Expanded patient base in the U.S. and internationally, including a successful launch in the U.K. in 2025. Positioned for further growth with geographic and pediatric label expansions.
Napazimone: Progressed in its registrational study for primary mitochondrial disease, targeting a $1 billion-plus opportunity. Enrollment expected to complete in 2026 with data readout in 2027.
Geographic Expansion: Joenja expanded into international markets, including the U.K., and is progressing regulatory submissions in Europe, Japan, and Canada. Over 80 patients are already receiving Joenja through early access programs in these regions.
Financial Performance: Achieved $376 million in revenues for 2025, a 27% increase year-on-year. Operating profit reached $26 million compared to a loss in 2024. Operating cash flow was $55 million, with a year-end cash position of $181 million.
Cost Management: Disciplined cost management led to stable operating expenses, with a 2% increase on a like-for-like basis excluding acquisition-related costs. G&A headcount reduction program announced in October 2025 is expected to save $9 million in 2026.
Pipeline Development: Completed enrollment for two leniolisib Phase II trials for larger prevalence PIDs, with data readout expected in the second half of 2026. Napazimone pivotal study enrollment to complete in 2026, with data readout in 2027.
Regulatory Milestones: Joenja's pediatric label expansion for APDS in the U.S. is under review, with a Type A meeting scheduled with the FDA. Regulatory submissions for Joenja are progressing in Europe, Japan, and Canada.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA regulatory challenges: The company received a complete response letter from the FDA regarding the regulatory submission for the pediatric label expansion for Joenja for the treatment of APDS in children ages 4 to 11. This indicates delays and additional work required to address clinical pharmacology and analytical batch testing methodology issues.
Competitive pressures in HAE market: RUCONEST faces increasing competition from newly launched therapies in the HAE market, which has started to impact growth. Some patients are trialing new therapies, although some have returned to RUCONEST.
Supply chain and inventory fluctuations: Quarterly revenue for RUCONEST is subject to fluctuations due to patient ordering patterns and channel inventory movements, with the first quarter typically being the lowest. Inventory drawdowns are expected to impact U.S. RUCONEST revenue growth by 7% to 9% year-on-year in Q1 2026.
Economic uncertainties and cost management: The company is increasing R&D investments significantly, which could strain financial resources. While cost management measures, such as a 20% G&A headcount reduction, have been implemented, the company must balance these with the need for sustained profitability.
Regulatory hurdles in international markets: The company is awaiting regulatory approvals for Joenja in Europe, Japan, and Canada. Delays or challenges in securing these approvals could impact the planned geographic expansion and revenue growth.
Dependence on RUCONEST and Joenja: The company’s revenue is heavily reliant on RUCONEST and Joenja. Any significant market or regulatory challenges affecting these products could have a substantial impact on financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Expectations: Pharming expects 2026 revenue between $405 million and $425 million, representing an 8% to 13% growth. This growth will be driven by continued RUCONEST growth and accelerating Joenja growth.
Operating Expenses: Operating expenses are expected to increase at a slower pace, with a range of $330 million to $335 million, including over $60 million of incremental R&D investments.
RUCONEST Growth: Continued growth is expected, particularly in the U.S., despite competitive dynamics. Mid-single-digit growth is anticipated at the midpoint of the revenue guidance range.
Joenja Growth: Accelerated growth is expected, driven by uptake in APDS patients above 12 years in the U.S. and potential future regulatory approvals internationally. Pediatric APDS indication remains a future growth driver.
Pipeline Developments: 2026 will see the materialization of potential value inflection points, including the completion of enrollment in the napazimone pivotal study and top-line data readout for leniolisib Phase II trials in the second half of the year.
Regulatory Milestones: The company expects clarity on the U.S. pediatric label extension for Joenja following an FDA Type A meeting in March. European and Japanese regulatory approvals for leniolisib are anticipated in the first half of 2026.
Financial Discipline: Pharming aims to maintain strong financial discipline, optimizing capital allocation to growth drivers and ensuring sustainable value creation for shareholders.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much of Joenja's growth this year is expected to come from the U.S. market versus international markets?
A:Joenja's growth in 2026 is expected to be fueled by both the U.S. and international markets. Approximately 70%-75% of the growth will come from the U.S., with the rest from international markets, including the U.K. and other new launch countries.
Q:Of the 61 eligible patients in the U.S. not on treatment, how many could be converted to paid therapy?
A:There is a substantial proportion of eligible and potentially reimbursable patients in the U.S. that could drive growth for Joenja in 2026. However, the process involves a lag due to the complex patient journey, including multiple physician visits, enrollment, and reimbursement processes.
Q:Do you have any commentary on how quickly RUCONEST patients return after trying oral treatments?
A:Patients who try other treatments and find their crises not properly controlled tend to return to RUCONEST quickly, as HAE is a severe disease requiring reliable treatment. Not controlling a crisis could be life-threatening.
Q:What is the lead rate-limiting step in discussions with the FDA regarding Type A meeting?
A:It is too soon to speculate on the lead rate-limiting step. The company is looking forward to engaging with the FDA to address their feedback and discuss a path forward. The questions raised by the FDA are considered addressable.
Q:Why are patients switching back to RUCONEST from new therapies?
A:Some patients who tried new acute and prophylactic agents in the HAE market have returned to RUCONEST within 3 to 6 months. RUCONEST offers a unique value proposition, particularly for high-attack patients who prioritize reliability and fast on-demand treatment.
Q:Are there notable variations in moving patients from early access to paid therapy between Europe, Japan, and Canada?
A:In international markets like Europe, Japan, and Canada, access to paid therapies is centrally driven, making the process slower initially due to reimbursement negotiations. However, once reimbursement is granted, the process becomes efficient.
Q:What are the next steps for Joenja in other primary immune deficiencies and Phase II readouts?
A:The company expects Phase II results later this year and plans to discuss the path forward with the FDA and other regulators. A Phase III randomized study is likely, but alternative mechanisms may be considered for rare diseases with plausible mechanisms.
Q:What are the timelines for getting patients in Japan and Canada on paid therapy for Joenja?
A:In Japan, the company plans to submit a price for reimbursement shortly, which takes about 3 months. Launch timelines are planned for the summer. More detailed reporting on international markets will follow as launches expand.
Q:How many patients in the U.K. are currently on paid therapy for Joenja?
A:The company has not disclosed the exact number of patients on paid therapy in the U.K. but plans to provide more detailed reporting as launches expand to more countries.
Q:Are you expecting the rate of patients on paid therapy for Joenja in the U.S. to pick up in 2026?
A:Yes, the company expects to accelerate patient enrollment and revenue growth for Joenja in 2026, building on the reaccelerated uptake and increased identification of APDS patients in 2025.
Q:What are the phasing considerations for costs in 2026, particularly around R&D and G&A?
A:The company expects 6%-8% growth in OpEx in 2026. Savings from the G&A reduction program will fully materialize, and marketing and sales costs will remain flat. Incremental investments will focus on advancing the pipeline.
Q:What is the company's focus regarding M&A and in-licensing opportunities?
A:The company is exploring opportunities to expand its pipeline, focusing on value-accretive transactions that complement its mission and growth platform. There is no urgency to pursue transactions hastily.
Q:What is the timeline for additional experiments on variants of uncertain significance (VUS) and their results?
A:The company is planning new experiments using base editing technology to generate more controls. Timelines and the number of patients to be reclassified are not yet determined, but updates will be provided as work progresses.
Q:Is there an unusually large inventory drawdown expected for RUCONEST in Q1?
A:Yes, there is a slightly higher inventory drawdown expected in Q1 due to market dynamics and a return to normalized inventory levels. Quarterly fluctuations in RUCONEST sales are not unusual.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the exact number of patients on paid therapy for Joenja in the U.K., stating that more detailed reporting will follow as launches expand to more countries.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abliva
FDA
HAE
Investor Day
Joenja sale
Leverne
Napazimone
PIDs
RUCONEST
Type meeting
United States
VUSs
approval
attack
child age
confidence
cost good
disease
dysregulation
enrollment
expansion
flow
investment
item
leniolisib
milestone payment
patient year
prevalence
progress
revenue
sale milestone
segment
study
therapy
treatment
PHAR Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call presents a positive outlook with raised revenue guidance, geographic expansion, and strong pipeline development. The Q&A section reveals optimism about Joenja's growth in the U.S. and international markets, despite some uncertainties in patient conversion rates. Financial discipline and a focus on value-accretive transactions further enhance the positive sentiment. The optimistic guidance and strategic focus on expanding Joenja's market presence are likely to drive a positive stock price movement over the next two weeks.
Canfor Corporation (CFP:CA) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call indicates significant challenges, particularly in Europe with EBITDA losses and high log costs. The Q&A highlights these issues, with management expecting improvements only by 2026. The company's financial health shows net debt and liquidity, but the uncertain path for Canfor Pulp and vague management responses on strategy further contribute to a negative outlook. While North American operations show some resilience, the overall sentiment leans negative due to European struggles and lack of clear strategic direction.
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals strong financial performance with a 32% revenue increase and improved margins, alongside optimistic guidance and a raised revenue forecast. Product developments, particularly Joenja's expansion, are promising. While some uncertainties exist, such as RUCONEST's withdrawal impact, the overall sentiment remains positive due to the strong growth trajectory and strategic direction.
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call presents a largely positive outlook with strong revenue and profit growth, increased cash reserves, and raised revenue guidance. Despite some execution challenges in G&A expense reduction and potential bottlenecks in patient reclassification, the market strategy and financial health are solid. The Q&A section highlighted management's confidence in overcoming these challenges. The positive sentiment is reinforced by the company's strategic geographic expansion and robust product performance, notably RUCONEST and Joenja. These factors suggest a positive stock price movement in the short term.
PHAR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
